<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941808</url>
  </required_header>
  <id_info>
    <org_study_id>19-PP-01</org_study_id>
    <nct_id>NCT03941808</nct_id>
  </id_info>
  <brief_title>Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo.</brief_title>
  <acronym>Vitisod</acronym>
  <official_title>Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo. A Randomized Double Blind Placebo Controlled Monocentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of the oxidative stress in vitiligo is supported by many studies but robust data are&#xD;
      lacking concerning their interest as therapeutic agents. The objective of the study is to&#xD;
      compare the association of GLISODIN (a gastro-protected superoxide dismutase) and Nb-UVB to&#xD;
      Nb-UVB and placebo for treating vitiligo.&#xD;
&#xD;
      Adult patients with non-segmental vitiligo affecting more than 5% of body surface area will&#xD;
      be included.&#xD;
&#xD;
      The main criteria of evaluation will be the VES score at 6 months compared to baseline in&#xD;
      both groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation Vitiligo</measure>
    <time_frame>At Baseline and at 6 weeks</time_frame>
    <description>Change from Baseline VES (Vitiligo Extend Score) at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patient</measure>
    <time_frame>At Baseline and at 6 weeks</time_frame>
    <description>Change from baseline DLQI at 6 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Vitiligo activity score</measure>
    <time_frame>At baseline and at 6 months</time_frame>
    <description>Change from vaseline SA-VES (self administrated VES) at 6 months</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glisodin tablet</intervention_name>
    <description>4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Vitiligo&#xD;
&#xD;
          -  Vitiligo, SOD, UVB&#xD;
&#xD;
          -  Non-segmental vitiligo with BSA&gt;5%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Criteria of non-inclusion&#xD;
&#xD;
               -  Segmental or mixed vitiligo&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Vitiligo lesions localized only on hands and feet&#xD;
&#xD;
               -  Immuno-suppressive drugs&#xD;
&#xD;
               -  Corticosteroids&#xD;
&#xD;
               -  Photosensitive drugs&#xD;
&#xD;
               -  Photodermatosis&#xD;
&#xD;
               -  Personal history of skin cancer&#xD;
&#xD;
               -  Allergy to gluten&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Passeron Thierry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Passeron</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritime</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

